Company news
Coya Therapeutics, Inc. (NASDAQ:COYA) news
Every Coya Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Est...
September 8, 2026
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
August 11, 2026
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
June 18, 2026
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
June 15, 2026
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
June 8, 2026
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
May 27, 2026
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 12, 2026
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
May 12, 2026
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting th...
April 9, 2026
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
April 2, 2026
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia,...
March 18, 2026
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
March 16, 2026
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape...
February 10, 2026
Coya Therapeutics Announces $11.1 Million Private Placement
January 30, 2026
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
January 20, 2026
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive ...
January 8, 2026
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for COYA 302 for the Treatment of Frontotemporal ...
January 6, 2026
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotem...
January 5, 2026
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for ...
December 23, 2025
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
December 9, 2025
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
November 25, 2025
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
November 12, 2025
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflam...
November 4, 2025
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Op...
October 27, 2025
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
October 24, 2025
Coya Therapeutics Announces Proposed Public Offering of Common Stock
October 23, 2025
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Disco...
October 7, 2025
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-...
September 29, 2025
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Later...
September 22, 2025
Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) ...
September 16, 2025
Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial
September 4, 2025
Coya Therapeutics to Participate at Upcoming September Investor Conferences
September 3, 2025
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic La...
August 25, 2025
Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
August 12, 2025
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’...
July 24, 2025
Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
July 22, 2025
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
June 18, 2025
Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin...
June 2, 2025
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
May 16, 2025
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
May 13, 2025
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025
May 8, 2025
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combin...
April 24, 2025
Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulat...
April 21, 2025
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
April 1, 2025
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
March 26, 2025
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
March 18, 2025
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonist...
February 25, 2025
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Follow...
February 6, 2025
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Infla...
January 21, 2025
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig F...
December 18, 2024